A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.

ABSTRACT:

Purpose

The identification of a molecular signature predicting the relapse of tamoxifen-treated primary breast cancers should help the therapeutic management of estrogen receptor-positive cancers.

Experimental design

A series of 132 primary tumors from patients who received adjuvant tamoxifen were analyzed for expression profiles at the whole-genome level by 70-mer oligonucleotide microarrays. A supervised analysis was done to identify an expression signature.

Results

We defined a 36-gene signature that correctly classified 78% of patients with relapse and 80% of relapse-free patients (79% accuracy). Using 23 independent tumors, we confirmed the accuracy of the signature (78%) whose relevance was further shown by using published microarray data from 60 tamoxifen-treat

SUBMITTER: Chanrion M 

PROVIDER: S-EPMC2912334 | biostudies-literature | 2008 Mar

REPOSITORIES: biostudies-literature